Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has become one of the most studied and commercially significant peptide therapies in modern medicine. Developed by Novo Nordisk and first approved by the FDA in 2017 for type 2 diabetes, semaglutide reached a second approval in 2021 under the Wegovy brand for chronic weight management — a milestone that repositioned it as a primary tool in obesity pharmacology. Its story begins with earlier GLP-1 analogs: a 2019 review in Frontiers in Endocrinology tracing the discovery and development of liraglutide and semaglutide describes how structural modifications to the native GLP-1 hormone, including fatty acid conjugation and amino acid substitutions, yielded a molecule with dramatically extended half-life and improved receptor binding compared to its predecessors.

Researchers find semaglutide interesting for several reasons beyond its glucose-lowering effects. The degree of weight loss it produces — averaging roughly 15% of body weight in the STEP clinical trial program — was historically associated only with bariatric surgery. This level of efficacy in a once-weekly injectable shifted the scientific consensus about what pharmacotherapy alone can achieve in obesity. The SELECT cardiovascular outcomes trial, published in Nature Medicine in 2024, further demonstrated durable weight loss over more than three years in people with obesity but without diabetes, while also showing reductions in major cardiovascular events.

Beyond metabolic disease, researchers are studying semaglutide's effects on the central nervous system, addiction pathways, kidney disease, heart failure, metabolic-associated steatohepatitis (MASH), and neurodegenerative conditions. Its ability to cross the blood-brain barrier and act on hypothalamic and brainstem appetite circuits has opened entirely new questions about GLP-1 receptor signaling in the brain. Animal studies published in JCI Insight in 2020 mapped the distributed neural pathways through which semaglutide reduces body weight in rodents, pointing to areas beyond simple appetite suppression. The compound's profile — a structurally modified human peptide with a week-long half-life, broad receptor distribution, and a large and growing clinical evidence base — makes it one of the most scientifically active compounds in endocrinology research today.

Semaglutide acts as a full agonist at the glucagon-like peptide-1 receptor (GLP-1R), a G protein-coupled receptor expressed widely across pancreatic beta cells, the gastrointestinal tract, the cardiovascular system, kidneys, and multiple brain regions. Binding of semaglutide to GLP-1R activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). In pancreatic beta cells, this cascade stimulates glucose-dependent insulin secretion — meaning insulin release is amplified only when blood glucose is elevated, reducing the hypoglycemia risk seen with older drug classes. Simultaneously, semaglutide suppresses glucagon secretion from pancreatic alpha cells, lowering hepatic glucose output.

The structural design of semaglutide is central to its pharmacology. Native GLP-1 has a plasma half-life of only one to two minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and renal clearance. Semaglutide overcomes this through two key modifications: substitution of alanine with aminoisobutyric acid at position 8 to resist DPP-4 cleavage, and attachment of a C18 fatty diacid chain at lysine-26 via a linker. The fatty acid chain enables strong, reversible binding to albumin in plasma, drastically extending the half-life to approximately one week and making subcutaneous once-weekly dosing viable.

In the brain, GLP-1 receptors are expressed in the hypothalamus, brainstem nucleus tractus solitarius, ventral tegmental area, and other regions involved in energy homeostasis and reward. A 2020 study in JCI Insight showed that semaglutide reduces body weight in rodents through distributed neural pathways including hypothalamic and hindbrain circuits, not solely through a single appetite-suppression mechanism. This central action leads to reduced hunger, increased satiety, and decreased caloric intake. Semaglutide also slows gastric emptying, which prolongs the feeling of fullness after meals. Together, the peripheral and central mechanisms produce the metabolic effects observed in clinical trials: lower blood glucose, reduced food intake, and significant body weight reduction.

The clinical evidence base for semaglutide is one of the largest assembled for any peptide therapeutic, spanning tens of thousands of participants across multiple indication-specific trial programs.

The STEP (Semaglutide Treatment Effect in People with obesity) program forms the backbone of the weight management evidence. STEP 2, published in The Lancet in March 2021, enrolled 1,210 adults with overweight or obesity and type 2 diabetes in a randomized, double-blind, placebo-controlled phase 3 trial. Participants receiving semaglutide 2.4 mg once weekly achieved a mean body weight reduction of 9.6% compared to 3.4% in the placebo group over 68 weeks, a statistically significant and clinically meaningful difference. A 2022 systematic review and meta-analysis published in the Journal of the ASEAN Federation of Endocrine Societies analyzed semaglutide's efficacy and safety for weight loss in obesity without diabetes, pooling data from multiple trials and confirming weight reductions averaging 10–15% and improvements in cardiometabolic markers across studies.

A 2024 study in Nature Medicine reported long-term weight loss outcomes from the SELECT trial, which enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes. Over a median follow-up exceeding three years, participants on semaglutide 2.4 mg maintained clinically significant weight loss while also showing a 20% relative risk reduction in major adverse cardiovascular events — a finding that extended the drug's research relevance beyond metabolic disease.

The SUSTAIN trial series examined semaglutide in type 2 diabetes. SUSTAIN 7, published in Lancet Diabetes & Endocrinology in April 2018, was a randomized open-label phase 3b trial comparing semaglutide to dulaglutide once weekly in 1,201 patients. Semaglutide 1 mg produced greater reductions in HbA1c (−1.5%) and body weight (−6.5 kg) than dulaglutide 1.5 mg, establishing semaglutide's superiority within the GLP-1 receptor agonist class on both outcomes.

Animal research has clarified mechanisms. A 2020 study in JCI Insight used rodent models to map the neural circuits through which semaglutide reduces body weight, identifying hypothalamic and brainstem pathways and demonstrating that the effect is not purely peripheral, establishing a foundation for research into central nervous system applications.

Safety literature has grown alongside efficacy data. A 2021 review in Frontiers in Endocrinology summarized the safety profile across the development program, identifying gastrointestinal events as the most frequent adverse findings. A 2024 study published in JAMA Ophthalmology raised a new concern, reporting an elevated risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed semaglutide — a finding requiring independent replication but noted by regulatory bodies. A 2023 review in Diabetes, Obesity and Metabolism consolidated the efficacy and safety literature and highlighted ongoing research gaps in pediatric populations, very long-term outcomes, and non-metabolic indications.

Clinical trials and FDA approvals have established specific dose regimens for semaglutide across its two approved indications. For type 2 diabetes (Ozempic), the approved doses are 0.5 mg, 1 mg, and 2 mg subcutaneously once weekly, with a starting dose of 0.25 mg weekly for four weeks for tolerability. For chronic weight management (Wegovy), the approved maintenance dose is 2.4 mg subcutaneously once weekly, reached through a structured escalation starting at 0.25 mg weekly and increasing every four weeks. In the STEP 2 trial (Lancet, 2021), the 2.4 mg once-weekly dose was used over 68 weeks. In SUSTAIN 7 (Lancet Diabetes Endocrinol, 2018), doses of 0.5 mg and 1 mg once weekly were studied against dulaglutide. An oral formulation (Rybelsus) is approved at 3 mg, 7 mg, and 14 mg daily for type 2 diabetes.

Semaglutide has been evaluated in thousands of participants across large phase 3 trials and carries an established safety profile that is better characterized than most peptide compounds in research. That said, several concerns — some emerging from post-marketing data — warrant attention.

Gastrointestinal adverse events are the most common class of side effects reported across trials. These include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, and they occur most frequently during dose escalation. In the STEP 2 trial, gastrointestinal events led to discontinuation in approximately 3–4% of participants in the semaglutide group. A 2021 review in Frontiers in Endocrinology systematically analyzed the safety data across the development program and confirmed that gastrointestinal effects were dose-dependent and typically transient, resolving as patients adapted to the drug.

Pancreatitis is a labeled warning for all GLP-1 receptor agonists, including semaglutide. Clinical trial data show the absolute incidence is low, but the risk is not zero and patients with a history of pancreatitis are generally excluded from treatment. Thyroid C-cell tumors were observed in rodent studies at suprapharmacological doses, leading to a black box warning regarding medullary thyroid carcinoma in the prescribing information. Human relevance of the rodent thyroid signal remains uncertain based on available data.

A 2024 study in JAMA Ophthalmology reported a statistically significant association between semaglutide use and nonarteritic anterior ischemic optic neuropathy (NAION), a rare form of optic nerve damage that can cause vision loss. The study was retrospective and observational, and the absolute risk remained small, but the finding was notable enough to prompt regulatory review. Independent replication is needed to establish causality.

Hypoglycemia risk is low when semaglutide is used as monotherapy, because its insulin-stimulating effect is glucose-dependent. The risk increases when combined with sulfonylureas or insulin. Gallbladder disease, including cholelithiasis, has been reported at higher rates in semaglutide-treated patients compared to placebo in pooled analyses, consistent with rapid weight loss as a contributing mechanism. Long-term safety data beyond three to four years remain limited, and safety in pregnancy, pediatric populations under 12, and patients with severe renal impairment continues to be studied.

Semaglutide holds FDA approval for two indications: type 2 diabetes (Ozempic, approved 2017) and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (Wegovy, approved 2021). An oral formulation, Rybelsus, was approved for type 2 diabetes in 2019. The compound is approved in the European Union, United Kingdom, Canada, and numerous other jurisdictions.

Active research is examining semaglutide across a wide range of conditions beyond its approved indications. Ongoing or recently completed trials are investigating its effects in metabolic-associated steatohepatitis (MASH), chronic kidney disease, heart failure with preserved ejection fraction, Parkinson's disease, Alzheimer's disease, alcohol use disorder, and other addiction-related conditions. The SELECT trial confirmed cardiovascular mortality benefits, and additional outcomes data from extended follow-up are expected. Key evidence gaps include long-term safety beyond four years, effects in adolescents, optimal use strategies for weight maintenance after stopping the drug, and the mechanisms underlying its apparent central nervous system effects.